Clinical Trials Logo

Filter by:
NCT ID: NCT00234065 Completed - Cerebral Infarction Clinical Trials

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Start date: December 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg, once daily).

NCT ID: NCT00233870 Completed - Fabry Disease Clinical Trials

A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

Start date: June 2004
Phase: Phase 4
Study type: Observational

The purpose of this survey is to identify any concerns regarding the following efficacy and safety-related issues in clinical practice with the new drugs "Fabrazyme for intravenous infusion 5mg" and "Fabrazyme for intravenous infusion 35mg" and to confirm the safety of these products in long-term use in the clinical setting. 1. New adverse drug reactions (ADRs) that cannot be predicted from the Precautions (in particular, clinically significant ADRs) 2. The incidence of ADRs under the actual conditions of use of the drug 3. Causal factors that might potentially affect safety 4. Efficacy evaluation in long-term use This survey will be conducted in accordance with the approval condition established for Fabrazyme: "To conduct a special surveillance of Efficacy and Safety in long term treatment and Pediatric with the drug."

NCT ID: NCT00233441 Completed - Atrial Fibrillation Clinical Trials

Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

MAIA
Start date: December 2004
Phase: Phase 2/Phase 3
Study type: Interventional

Double blind study to evaluate the efficacy and tolerability of SSR149744C and select a dose to be further investigated in the maintenance of sinus rhythm after electrical, pharmacological or spontaneous conversion of AF/AFL.

NCT ID: NCT00233389 Completed - Stomach Ulcer Clinical Trials

Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer

Start date: April 30, 2004
Phase: Phase 4
Study type: Interventional

To examine the efficacy of continued administration of rebamipide following bacteria eradication therapy in patients with H. pylori-positive active gastric ulcer in a placebo-controlled, double-blind study

NCT ID: NCT00233363 Completed - Sjogren's Syndrome Clinical Trials

Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome

Start date: April 15, 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to exploratively investigate the clinical efficacy of rebamipide on dry mouth in patients with Sjögren's syndrome in comparison with placebo.

NCT ID: NCT00232661 Completed - Breast Cancer Clinical Trials

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

Start date: August 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.

NCT ID: NCT00232648 Completed - Asthma Clinical Trials

Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma

Start date: January 2004
Phase: Phase 3
Study type: Interventional

This study is as an extension study of SD-004-0765, to assess the safety profile of long-term use of budesonide inhalation suspension in Japanese young children with bronchial asthma. Children completing study SD-004-0765 continued administration of budesonide inhalation suspension as judged by the investigator; the dose is adjusted as appropriate within the range of 0.25 to 1.0 mg per day administered once or twice daily, according to the symptoms.

NCT ID: NCT00232375 Completed - Clinical trials for GAD Ab Positive Clinically Type 2 Diabetic Patients

Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes

Start date: January 1996
Phase: N/A
Study type: Interventional

We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a preferable outcome to reverse or preserve beta cell function in the patients with diabetes that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent autoimmune diabetes in adult (LADA).

NCT ID: NCT00232011 Completed - Atopic Dermatitis Clinical Trials

Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

Start date: May 2004
Phase: Phase 3
Study type: Interventional

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult patients with atopic dermatitis. This study is a 6-month extension study following core study. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

NCT ID: NCT00231998 Completed - Atopic Dermatitis Clinical Trials

Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis

Start date: May 2004
Phase: Phase 3
Study type: Interventional

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of Pimecrolimus cream will be evaluated in Japanese pediatric patients with atopic dermatitis. This study is a 6-month extension study following core study. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES